PapersPMID:20447305
Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial.
What moved
1 findingHow to read these marks →- Increases health-related quality of life
very limited
“Expressed as percent of baseline values, significantly enhanced improvement in average pain measures and in quality of life scores occurred after treatment in the agmatine group (26.7% and 70.8%, respectively) as compared with placebo (6.0% [P </= 0.05] and 20.0% [P </= 0.05], respectively).”
- Study
- RCT
- Duration
- 14 days
- Dose studied
- agmatine sulfate 2.670 g/day for 14 days
- Population
- Adults with herniated lumbar disc-associated radiculopathy, randomised double-blind to agmatine sulfate or placebo; analysed n = 31 agmatine and 30 placebo; abstract only
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Participants diagnosed with herniated lumbar disc-associated radiculopathy
- Participants
- not reported
- Comparator
- placebo
- Duration
- 14 days
- Endpoints measured
- 2